ArticleFrontiers in public health2026
Antimicrobial resistance in nontyphoidal
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: State and local health departments and the Centers for Disease Control and Prevention (CDC) routinely investigate multistate outbreaks of salmonellosis associated with backyard poultry (BYP). Here, we describe antimicrobial resistance in multistate outbreaks of nontyphoidal salmonellosis associated with BYP from 2018 to 2023. Methods: We analyzed patient and outbreak data from CDC's National Antimicrobial Resistance Monitoring System and System for Enteric Disease Response, Investigation, and Coordination databases. Isolate resistance was determined by antimicrobial susceptibility testing or predicted by whole genome sequencing. We classified isolates as resistant, multi-drug resistant (MDR; resistant to ≥3 antimicrobial classes), or having clinically relevant resistance (CRR; resistant to ampicillin, azithromycin, ceftriaxone, or trimethoprim-sulfamethoxazole; or nonsusceptibility to ciprofloxacin), and outbreaks as resistant, MDR, or CRR if ≥3 isolates and ≥10% of isolates met the corresponding resistance definitions. Statistical analyses comparing patient variables, outbreak size, and annual number of outbreaks with resistance status were performed. Results: Among 78 multistate BYP-associated salmonellosis outbreaks, 36 (46%) exhibited resistance, 10 (13%) were classified as MDR, and 12 (15%) were classified as CRR. Enteritidis was the most frequent serotype, causing 22 (28%) outbreaks; three were resistant (two CRR only outbreaks, one CRR and MDR outbreak). Among the 6,262 patient isolates included in multistate BYP-associated salmonellosis outbreaks, 2,248 (36%) were resistant, 209 (3%) were MDR, and 395 (6%) were CRR. Discussion: Although nearly half of BYP-associated salmonellosis outbreaks and one-third of outbreak isolates were resistant, CRR and MDR outbreaks and isolates were infrequent. Continued monitoring for antimicrobial resistance is warranted because of the persistence of BYP-associated salmonellosis and the potential for BYP to serve as a reservoir for resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.